Cargando…
Secondary glaucoma after intravitreal dexamethasone implant (Ozurdex) injection in patients with retinal disorder: A retrospective study
PURPOSE: To investigate the rate of secondary glaucoma after intravitreal (IV) dexamethasone implant (ozurdex) 0.7 mg injection in a retinal disorder over a clinical treatment period of 2 years in a tertiary eye care center. METHODS: Retrospective study based on the records of patients receiving IV...
Autores principales: | Sweta, VD, Shibi Dev, BN, Sandhya, R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023975/ https://www.ncbi.nlm.nih.gov/pubmed/35086242 http://dx.doi.org/10.4103/ijo.IJO_684_21 |
Ejemplares similares
-
Fractured dexamethasone implant (OZURDEX®) following intravitreal injection
por: Aljohani, Saud M., et al.
Publicado: (2021) -
Intravitreal Dexamethasone Implant (Ozurdex) for Refractory Macular Edema Secondary to Retinitis Pigmentosa
por: Örnek, Nurgül, et al.
Publicado: (2016) -
Intravitreal Dexamethasone Implant (Ozurdex) in Coats’ Disease
por: Saatci, Ali Osman, et al.
Publicado: (2013) -
Effect of dexamethasone intravitreal implant (Ozurdex®) on corneal endothelium in retinal vein occlusion patients: Corneal endothelium after dexamethasone implant injection
por: Güler, Hatice Ayhan, et al.
Publicado: (2018) -
Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment
por: Garweg, Justus G., et al.
Publicado: (2016)